Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ICER Views CAR-T Therapies Kymriah, Yescarta As Cost Effective

22 Dec 2017

• By Mandy Jackson

Doctor holding out your piggy bank wanting payment/ Your Savings To Pay Bill, insert coins to it,Stethoscope financial checkup or saving for medical insurance costs money plan fee Lifestyle concept

Related Content

Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS

31 Aug 2017

What's New And What's Next In CAR-T After ASH

16 Dec 2017

Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah

19 Oct 2017

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

31 Aug 2017

Additional Topics

Cost Effectiveness ImmunoOncology Pricing Strategies Commercial Cancer BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.